These results, together with previous reports showing that high p16INK4A expression in the tumour stroma was strongly associated with high risk of recurrence56 or poor survival57 in some types of cancer, suggest that there might be the negative side effects of CDK inhibitor drugs used for cancer treatment. This evidence concerns the gene CDKN2A and cancer.